Cargando…
Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice
The JAVELIN Bladder 100 phase III trial led to the incorporation of avelumab first-line (1L) maintenance treatment into international guidelines as a standard of care for patients with advanced urothelial carcinoma (UC) without progression after 1L platinum-based chemotherapy. JAVELIN Bladder 100 sh...
Autores principales: | Grivas, P., Grande, E., Davis, I.D., Moon, H.H., Grimm, M.-O., Gupta, S., Barthélémy, P., Thibault, C., Guenther, S., Hanson, S., Sternberg, C.N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685024/ https://www.ncbi.nlm.nih.gov/pubmed/37976999 http://dx.doi.org/10.1016/j.esmoop.2023.102050 |
Ejemplares similares
-
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
por: Powles, Thomas, et al.
Publicado: (2023) -
The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape
por: Koshkin, Vadim S., et al.
Publicado: (2019) -
Clinical evidence and insights supporting the use of avelumab first‐line maintenance treatment in patients with advanced urothelial carcinoma in the Asia‐Pacific region
por: Eto, Masatoshi, et al.
Publicado: (2022) -
Diffuse Alveolar Hemorrhage With Avelumab Maintenance Therapy
por: Li, Si, et al.
Publicado: (2021) -
Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
por: Tomita, Yoshihiko, et al.
Publicado: (2022)